|SUBJECT:||M.S. Thesis Presentation|
|TIME:||Friday, September 22, 2017, 8:30 a.m.|
|PLACE:||Technology Enterprise Park, 104|
|TITLE:||Impact of Simulated MitraClip on Forward Flow Obstruction in the Setting of Mitral Leaflet Tethering|
|COMMITTEE:||Dr. Ajit Yoganathan, PhD, Chair (BME)
Dr. Rudolph Gleason, PhD (ME)
Dr. Vasilis Babaliaros, MD (Emory School of Medicine)
The catheter-based MitraClip device (Abbott Vascular, Santa Clara, CA) is currently the only widely-used and FDA approved endovascular mitral repair device, with over 35,000 patients treated worldwide to-date. MitraClip works by clipping the mitral leaflets together at the site of mitral regurgitation (MR). This closes the regurgitant orifice, while still allowing the leaflets to open to either side of the device, thereby creating a “double orifice”. In many cases, multiple MitraClip devices are used to treat MR, though placement of additional devices can further reduce mitral valve area and increase mean mitral valve gradient, leading to mitral stenosis (MS), or obstruction of forward flow through the MV. In functional MR (FMR) in particular, MS severity after MitraClip may be further exacerbated by diastolic restriction of the anterior mitral leaflet (AML), which is caused by severe dilatation of the left ventricle and papillary muscle displacement. However, limited data on the effect of AML tethering on MS severity after MitraClip exists.